Видео ютуба по тегу Medicines: Atezolizumab

Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC
Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC
Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC
Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC
Atezolizumab + Bevacizumab in Treatment-Naïve mRCC
Atezolizumab + Bevacizumab in Treatment-Naïve mRCC
ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC
ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC
Atezolizumab’s Role in Treating Nondriver NSCLC
Atezolizumab’s Role in Treating Nondriver NSCLC
Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCC
Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCC
The FDA Approval of Atezolizumab in Bladder Cancer
The FDA Approval of Atezolizumab in Bladder Cancer
Atezolizumab and Bevacizumab Studied in Patients With Metastatic RCC
Atezolizumab and Bevacizumab Studied in Patients With Metastatic RCC
Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC
Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC
Dr. Horn Discusses Next Steps With Atezolizumab in SCLC
Dr. Horn Discusses Next Steps With Atezolizumab in SCLC
IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC
IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC
Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC
Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC
Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumab
Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumab
Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma
Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma
Atezolizumab Versus Other Immunotherapy Options
Atezolizumab Versus Other Immunotherapy Options
UK's National Health Service to roll out first cancer treatment jab | WION
UK's National Health Service to roll out first cancer treatment jab | WION
Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC
Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC
Dr. Overman on the Combination of Atezolizumab and Bevacizumab in HCC
Dr. Overman on the Combination of Atezolizumab and Bevacizumab in HCC
Molecular Targeted Therapies for Advanced HCC
Molecular Targeted Therapies for Advanced HCC